European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
about
Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessmentsManagement of psoriasis patients with hepatitis B or hepatitis C virus infectionConsiderations for Systemic Treatment of Psoriasis in Obese Patients.[Topical therapy of the scalp].Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies.Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.Time, PASI and DLQI of psoriasis patients who "drop out" of clinical trials on etanercept due to "lack of efficacy" - a pooled analysis from ten clinical trials.Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.Diagnosing liver fibrosis: a narrative review of current literature for dermatologists.Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases.Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.Certolizumab pegol for the treatment of psoriasis.Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE.Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP).Apremilast: A Review in Psoriasis and Psoriatic Arthritis.Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER)."Inflammatory skin march" in atopic dermatitis and psoriasis.A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.Treatment of severe psoriasis in children: recommendations of an Italian expert group.Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis.[Current guidelines in dermatology : A selection of clinically relevant recommendations].Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry.Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.Treatment Approaches to Moderate to Severe Psoriasis.Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis.Drug survival rates and reasons for drug discontinuation in psoriasis.Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.Old and New Biological Therapies for Psoriasis.Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma.Optimizing acitretin use in patients with plaque psoriasis.First-line systemic treatment of psoriasis: staying conventional or going biologic?
P2860
Q26767276-572C7115-EDE9-4477-8397-B68D8F009206Q28066898-8B3C8ECB-FCE6-4692-95DA-7DF24BDC8EE4Q28078157-C210E173-C5CF-4CED-8F60-371042EAED56Q30249013-D0E1460E-B30A-4D33-8826-8DF4B702335FQ30313345-C82A0BF8-EC8A-4472-9D42-C9D977DDFA0BQ34046298-1407177F-5F18-4D81-82C9-5B7767C1A4CEQ36316015-BF26787A-97F2-4FE0-A7B8-00803F66671EQ38644270-9776F025-2C5D-4223-AF98-2C7133BC8A74Q38712213-37BDB8AD-9B4F-403E-8D76-5A4A316118DAQ38727735-B06A06DE-F04F-4012-94A2-6CF48BDBFD8FQ38764716-E8B87F18-662C-4A52-AFF7-F9B303E11AF6Q38780434-F5A196A1-C0AF-4DC0-AA25-6733CEA74840Q38907492-E25B0B10-A20D-44A2-96B6-A9EF5728570EQ38907998-E4F2AE02-50CB-484B-8729-2CA2CE44AB6AQ38920742-0A0E9AE8-371C-4174-9FEC-470E662E0768Q38960108-23CC8B00-7EDE-40C7-93E4-52CB7921E01CQ38976796-6BA36910-3842-4A26-918F-435E789CA3FCQ38990571-352CBA86-528B-4E7A-8976-08690B0BDD97Q39025609-DD267EC1-CDAF-4493-B3D4-AACC3C673F14Q39124718-07B0C5BB-93B5-44A6-8B67-0EB3C29326D9Q39141679-112C191E-57E2-48AD-8F9C-C0D2E00BC6F0Q39239428-3F65EE92-5E19-4E2A-9FFA-4D9F257EBB4EQ39377564-26FC134A-2222-41EE-A503-FD920E43B7D9Q39601823-EEAB5120-F5A6-4413-9C0D-748559A2AE20Q39738126-0CBB16E7-03BF-40C2-9B05-3E844D0A6C14Q40045451-8E48EABA-2620-45C0-8223-5E32F7B6F492Q40048725-D119F310-9354-49E8-BEDC-165E9817DDA3Q40081737-677762FF-5DE1-419B-98C4-31718006A6B8Q40261663-E42BB2FE-5B81-4F83-AF09-05DEFB856033Q40725560-F08E5F37-933E-4036-8063-07230E60C33CQ44104600-54A0792F-F619-401B-A86E-49B6E35AF8A1Q45636613-4FB9CEC8-A8A8-46E0-93A7-32C2956D6ECEQ47151665-8581298D-15D4-4887-9A05-47D9B092BD5AQ47318089-494AFA64-D207-426C-BF02-E39EF948D6DCQ47624590-6EA70394-DEBB-4297-B4E5-38F68D0FE289Q47786696-B953462E-4C81-420F-AD4B-7559365493E3Q47859049-B07AF199-1656-4F3F-BB59-C540EDB92179Q48089618-61EECC40-C8F4-49EB-B65F-5330FDB71BE5Q48133364-5568E21B-B638-4109-9B08-9040D38AAE7FQ48156161-0244A22D-7A1B-4244-989D-352FBA105595
P2860
European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
European S3-Guidelines on the ...... cooperation with EADV and IPC.
@en
European S3-Guidelines on the ...... cooperation with EADV and IPC.
@nl
type
label
European S3-Guidelines on the ...... cooperation with EADV and IPC.
@en
European S3-Guidelines on the ...... cooperation with EADV and IPC.
@nl
prefLabel
European S3-Guidelines on the ...... cooperation with EADV and IPC.
@en
European S3-Guidelines on the ...... cooperation with EADV and IPC.
@nl
P2093
P50
P356
P1476
European S3-Guidelines on the ...... cooperation with EADV and IPC.
@en
P2093
A D Ormerod
E M de Jong
M Maccarone
N Yawalkar
P304
P356
10.1111/JDV.13354
P50
P577
2015-10-19T00:00:00Z